Managing pandemic-driven dry eye with nutrition
Peter J. Polack, MD, FACS, of Ocala Eye, discusses how proper patient education and nutrition have been key to managing an increase in dry eye patients during the pandemic.
Related Articles
Study: Pediatric eye care deserts are a growing issue
Researchers examined disparities in service coverage of pediatric ophthalmologists and pediatric optometrists in relation to patient demographics to cast a light on at-risk populations and…
Eyenovia provides clinical, scientific update on FDA-approved products Mydcombi and clobetasol propionate ophthalmic suspension
The company announced results from a Phase IV study of tropicamide and phenylephrine hydrochloride ophthalmic spray 1%/2.5% (Mydcombi) designed to characterize the efficacy and duration…
ASCRS 2024: Tackling unconscious gender bias in ophthalmology, industry, and medicine
Neda Nikpoor, MD, urges audience members to become more empowered in making small but meaningful, evidence-based changes in combating unconscious gender bias.
Interactive online tool, Vision Simulator, highlights vision loss caused by retinal diseases
The tool shows disease progression and vision loss simulations for multiple diseases such as AMD, XLRP, and achromatopsia
Deep learning model for AI: Stopping nascent GA in its tracks
Researchers found the model demonstrated “near-perfect” detection capabilities.
Ocugen completes dosing of subjects with geographic atrophy in Cohort 2 of Phase 1/2 ArMaDa clinical trial of OCU410
According to the company, OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA gene.
Deep learning model for AI: Stopping nascent GA in its tracks
Researchers found the model demonstrated “near-perfect” detection capabilities.
Bausch + Lomb announces results from a clinical study of a novel daily nutritional supplement for dry eyes
The company expects to launch the supplement in the US, which features a proprietary blend of ingredients including lutein, zeaxanthin isomers, curcumin and vitamin D3,…
Eyenovia provides clinical, scientific update on FDA-approved products Mydcombi and clobetasol propionate ophthalmic suspension
The company announced results from a Phase IV study of tropicamide and phenylephrine hydrochloride ophthalmic spray 1%/2.5% (Mydcombi) designed to characterize the efficacy and duration…
Multiple companies announce data presentations at ARVO 2024
Akari Therapeutics, Ocuphire Pharma, and PharmAbcine are among the companies that have shared their plans for presentations at the ARVO annual conference in Seattle, Washington.